Burkholderia pseudomallei in cystic fibrosis patients reported in the literature

ReferenceAge (yr), sexOriginClinical presentationTreatmentaOutcome and follow-up
420, maleMalaysiaNDbNDND
1738, maleThailandMultiple lung infectionsi.v. CAZ, PIP, and TZP with or without aminoglycosides or CIP for 2 wkMultiple exacerbations, at least 7 yr of documented colonization
1825, femaleThailandAcute lung infectionContinuous i.v. CAZ + SXT for 6 wk + oral SXT, DOX, and CHL for 30 wkClinical recovery, eradication of B. pseudomallei, 1 yr of follow-up
69, maleAustraliaAcute lung infection and bacteremiai.v. CAZ + TOB, CAZ + MEM, SXT, and MEM; duration of treatment NDClinical recovery after prolonged therapy, development of resistance to multiple drugs
67.5, femaleAustraliacNDOral DOXClinically healthy, B. pseudomallei in sputum for a time, follow-up ND
610, maleAustraliaColonization, mild infectioni.v. CAZ + SXT for 2 wk + SXT for 3 moHealthy, eradication of B. pseudomallei, 18 mo of follow-up
638, maleAustraliaAcute lung infectioni.v. CAZ + TOB, duration NDB. pseudomallei recovered 3 mo after completion of therapy
1423, maleAustraliaPulmonary exacerbations; severe respiratory infectionOral SXT + AMC; i.v. CAZ + MEM + oral SXT with or without oral TET and CIP for 8 wkDeath, persistent recovery of B. pseudomallei from sputum, follow-up ND
1236, maleAustraliaFrequent pulmonary exacerbationsi.v. CAZ, MEM, and oral SXT either alone or in combination; oral TET or SXT between exacerbationsProgressive deterioration, persistent recovery of B. pseudomallei from sputum, follow-up ND
1415, maleAustraliaAsymptomaticNoneFollow-up ND
1424, femaleAustraliacTwo severe exacerbationsi.v. CAZ + MEM + TOB for 3 wkClinically successful treatments, microbiologic outcome ND
117, maleMalaysiaChronic worsening respiratory symptoms and deteriorating lung functioni.v. SXT + CAZ for 2 mo followed by oral DOX + SXT for 4 moLung function recovery, negative sputum cultures, 5 mo of follow-up
  • a i.v., intravenous; AMC, amoxicillin-clavulanic acid; CAZ, ceftazidime; CIP, ciprofloxacin; DOX, doxycycline; MEM, meropenem.

  • b ND, not described.

  • c Subtropical region.